Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03637517 · ClinicalTrials.gov registry record · Phase 1
Malaria: Relative Bioavailability and Food Effect of DSM265
A Phase 1 study, sponsored by Medicines for Malaria Venture.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03637517: Completed Phase 1 study, sponsored by Medicines for Malaria Venture.
NCT03637517 is a Phase 1 study that has completed, run by Medicines for Malaria Venture. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03637517, a Phase 1 study, has completed, sponsored by Medicines for Malaria Venture.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
Phase 1 study designed to evaluate the relative bioavailability of a single dose of a test formulation, DSM265-TPGS 34% SDD powder in comparison with a reference DSM265 25% SDD powder formulation used in early clinical trials.
Primary Outcome
Maximum observed DSM265 plasma concentration
Interventions
- DRUG DSM265-TPGS 34% SDD, 400 mg fasted
- DRUG DSM265-TPGS 34% SDD, 400 mg fed
- DRUG DSM265 25% SDD, 400 mg fasted
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-10-03 |
| Est. Completion | 2018-11-19 |
| Phase | Phase 1 |
What the finished NCT03637517 record still lists
NCT03637517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 3 interventions - of which DSM265-TPGS 34% SDD, 400 mg fasted is the first listed.
NCT03637517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03637517 about?
NCT03637517 is a clinical study titled "Malaria: Relative Bioavailability and Food Effect of DSM265". Phase 1 study designed to evaluate the relative bioavailability of a single dose of a test formulation, DSM265-TPGS 34% SDD powder in comparison with a reference DSM265 25% SDD powder formulation used in early clinical trials.
What is the current status of trial NCT03637517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2018-10-03. Estimated completion is 2018-11-19.
What interventions are being tested in trial NCT03637517?
The interventions under investigation include: DSM265-TPGS 34% SDD, 400 mg fasted (DRUG), DSM265-TPGS 34% SDD, 400 mg fed (DRUG), DSM265 25% SDD, 400 mg fasted (DRUG).
Who is sponsoring clinical trial NCT03637517?
This trial is sponsored by Medicines for Malaria Venture, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03637517's enrollment target sits among peer trials
42 1105th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI